Apr 12, 2012 11:46am EDT OPKO Health Announces the Start of Phase 3 Clinical Trials of Rolapitant for the Prevention of CINV
Apr 03, 2012 8:55am EDT OPKO Health Announces License Agreement for OPKO’s Alzheimer’s Diagnostic Technology
Mar 09, 2012 8:50am EST OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks Brain Cell Destruction in Parkinson’s Disease